Companies / ABT vs REGN
ABT vs REGN: Abbott Laboratories and Regeneron Pharmaceuticals
Abbott Laboratories (ABT) reported $44.3B in revenue against a 14.7% net margin, while Regeneron Pharmaceuticals (REGN) reported $14.3B at a 31.4% net margin, most recently.
| Metric | ABT | REGN |
|---|---|---|
| Revenue | $44.3B | $14.3B |
| Net Income | $6.5B | $4.5B |
| Gross Margin | 56.4% | — |
| Operating Margin | 18.2% | 24.9% |
| EPS (Diluted) | $3.72 | $41.48 |
| Free Cash Flow | $7.4B | $4.1B |
| Total Debt | $12.9B | $2.7B |
| P/E Ratio | 33.7× | 18.6× |
| P/B Ratio | n/m | n/m |
| Stock Price | $112.71 | $910.75 |
Free: last 5 years
| Fiscal year | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| REGN Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |